Afshin Dowlati, MD
Schedule an Appointment
Biography
- Lucile and Robert H Gries Endowed Director, Center for Cancer Drug Development, University Hospitals
- Director, Thoracic Oncology Program, UH Seidman Cancer Center
- Director, Thoracic Oncology, UH Cleveland Medical Center
- Director, Phase I Drug Development Program, UH Cleveland Medical Center
- Professor, CWRU School of Medicine
Expertise
- Experimental Therapeutics
- Hematology/Oncology
- Lung Cancer
- Phase I Clinical Trials
- Thoracic Cancer
Languages Spoken
English, French, Farsi
Office Locations
Patient Experience Reviews
4.9 out of 5
87 Ratings
Patient Comments (28)
Reviewed On 5/1/2021
one of the nicest most caring doctors that I have ever had.
Reviewed On 5/1/2021
Consistent with previous positive experience.
Reviewed On 5/1/2021
good Answered all my questions
Reviewed On 4/1/2021
I cannot speak too highly of Dr. Dowlati and his team, or everyone I have so far come into contact with at UH Seidman Center on the main campus.
Reviewed On 4/1/2021
My oncologist is great. He is always concerned about my well being
Reviewed On 3/1/2021
Dr. Dowlati is a great physician and I appreciate his hard work.
Reviewed On 3/1/2021
Good
Reviewed On 3/1/2021
A very good experience
Reviewed On 2/1/2021
excellent
Reviewed On 2/1/2021
Dr Dowlati is very caring and patient oriented physician. ***
Reviewed On 1/1/2021
excellent staff, excellent doctor, professional, compassionate & helpful.
Reviewed On 1/1/2021
Dr. Diwali is the best. His staff is excellent!. The staff and nurses, *** in the infusion department are excellent and very compassionate. *** and l love them!!!
Reviewed On 1/1/2021
I am very happy with the doctor ***
Reviewed On 12/1/2020
good
Reviewed On 12/1/2020
I have been very pleased with Dr. Dowlati's care. He has always been supportive of me during my illness and has offered me choice in my treatment.
Reviewed On 12/1/2020
My Dr is amazing and I am very grateful. ***
Reviewed On 11/1/2020
attentive to my needs with sensitivity and caring attitude. Provider and nurse pa engaged professionally and personally with me.
Reviewed On 10/1/2020
Very engaged in our discussions and wants feedback on my health status. Has positive attitude when speaking to me, yet transparent with my situation.
Reviewed On 10/1/2020
excellent
Reviewed On 9/1/2020
I have always had good experiences at Dr. Dowlati Office... He has always showed me that he cares about helping me be well.
Reviewed On 9/1/2020
Care provider is a chemo-oncologist. He and his staff rate an A++++++ ***
Reviewed On 9/1/2020
He was exceptional. Just a wonderful caring man and so thorough.
Reviewed On 8/4/2020
excellent doctor & staff! very professional & caring!
Reviewed On 8/4/2020
Dr. Dowlati is an amazing doctor, very kind & thorough. ***
Reviewed On 8/4/2020
Everything about my consultation with Dr. Dowlati for a second opinion was outstanding. He was able to give me a look at my medical data with a slightly different perspective, which helped me understand my current health issues better. I really appreciate that!
Reviewed On 8/4/2020
I am so fortunate to have Dr. Dowlati as my Dr.
Reviewed On 8/4/2020
*** It's great to be seen by an oncologist who specializes in lung cancer. Thank you for your expertise, Dr Dowlati.
Reviewed On 8/4/2020
Personal, caring, deliberate, calming, provides an holistic approach. Very sincere, with solid listening skills.
Board Certifications
- Medical Oncology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Education
Residency | Internal Medicine
Internal Medicine - University Hospitals Of Cleveland (1998 - 2000)
Fellowship | Hematology/Oncology
Hematology/Oncology - University Hospitals Of Cleveland (1996 - 1998)
Internship | Internal Medicine
Internal Medicine - Universite De Liege Faculte De Medecine (1992 - 1996)
Medical Education
Universite De Liege Faculte De Medecine (1992)
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Afshin Dowlati did not disclose any Outside Relationships with Industry.